CCM
CSTL icon

Capstone Capital Management’s Castle Biosciences CSTL Stock Holding History

Capstone Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,446
Closed -$251K – 65
2025
Q4 		$251K Buy
+6,446
New +$208K 0.24% 96

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capstone Capital Management's CSTL Position: Q1 2026 in Review

Capstone Capital Management sold out of Castle Biosciences (CSTL) in Q1 2026, closing a stake of 6,446 shares — an estimated $251K sold.

Capstone Capital Management first reported a position in CSTL in Q4 2025 and held it in 1 quarter. The position peaked at $251K in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Capstone Capital Management reported no remaining Castle Biosciences position as of Q1 2026 after selling out during the quarter.
  • Capstone Capital Management sold 6,446 Castle Biosciences shares in Q1 2026, an estimated $251K.
  • Capstone Capital Management first reported a position in Castle Biosciences in Q4 2025 and held it in 1 quarter.
  • Capstone Capital Management's Castle Biosciences position peaked at $251K in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Capstone Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.